{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:03:35Z","timestamp":1789704215369,"version":"4.0.1"},"reference-count":123,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Immune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (PLTs) by B-cells, the activation of the complement system, phagocytosis by macrophages mediated by Fc\u03b3 receptors, the dysregulation of T cells, and reduced bone marrow megakaryopoiesis. ITP is commonly manifested with skin and mucosal bleeding, and it is a diagnosis of exclusion. In some ITP cases, the disease is self-limiting, and treatment is not required, but chronic-persistent disease can also be developed. In these cases, anti-CD20 monoclonal antibodies, such as rituximab and thrombopoietin (TPO) receptor agonists, can be used. TPO agonists have become standard of care today. It has been reported in the published literature that the efficacy of TPO-RAs can be up to 80% in the achievement of several end goals, such as PLT counts. In the current literature review, the data regarding the impact of TPO agonists in the pathogenesis of ITP and treatment outcomes of the patients are examined. In the era of precision medicine, targeted and individualized therapies are crucial to achieving better outcomes for pediatric patients with ITP, especially when chronic refractory disease is developed.<\/jats:p>","DOI":"10.3390\/cimb47010065","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:32:52Z","timestamp":1737376372000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"first","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Children & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-2605","authenticated-orcid":false,"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Children & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/pbc.26003","article-title":"Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study","volume":"63","author":"Neunert","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_2","first-page":"e69635","article-title":"Diagnosis and Management of Immune Thrombocytopenia in Paediatrics: A Comprehensive Review","volume":"16","author":"Thakur","year":"2024","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Terrell, D.R., Neunert, C.E., Cooper, N., Heitink-Poll\u00e9, K.M., Kruse, C., Imbach, P., K\u00fchne, T., and Ghanima, W. (2020). Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina, 56.","DOI":"10.3390\/medicina56120667"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wei, P. (2010). Thrombopoietin Factors. Hematopoietic Growth Factors in Oncology, Springer.","DOI":"10.1007\/978-1-4419-7073-2_5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12935-019-0779-0","article-title":"Megakaryocytic Dysfunction in Immune Thrombocytopenia Is Linked to Autophagy","volume":"19","author":"Sun","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_7","first-page":"2867","article-title":"Prolonged Response after TPO-RA Discontinuation in Primary ITP: Results of a Prospective Multicenter Study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin Receptor Agonists: Ten Years Later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of Terminology, Definitions and Outcome Criteria in Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2020006480","article-title":"An Update on Pediatric ITP: Differentiating Primary ITP, IPD, and PID","volume":"140","author":"Grace","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding Manifestations and Management of Children with Persistent and Chronic Immune Thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group (ICIS)","volume":"121","author":"Neunert","year":"2013","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1542\/peds.2012-2021","article-title":"Patterns of Inpatient Care for Newly Diagnosed Immune Thrombocytopenia in US Children\u2019s Hospitals","volume":"131","author":"Kime","year":"2013","journal-title":"Pediatrics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The Incidence and Clinical Burden of Immune Thrombocytopenia in Pediatric Patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Giordano, P., Lassandro, G., di Meo, N.A., Palladino, V., Lovrencic, B., Spinelli, M., Reale, L., and Jankovic, M. (2019). A Narrative Approach to Describe QoL in Children With Chronic ITP. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00163"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(01)07219-1","article-title":"Intercontinental Childhood ITP Study Group Newly Diagnosed Idiopathic Thrombocytopenic Purpura in Childhood: An Observational Study","volume":"358","author":"Imbach","year":"2001","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The Incidence of Immune Thrombocytopenic Purpura in Children and Adults: A Critical Review of Published Reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/asheducation-2018.1.568","article-title":"Evidence-Based Management of Immune Thrombocytopenia: ASH Guideline Update","volume":"2018","author":"Neunert","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lardinois, B., Favresse, J., Chatelain, B., Lippi, G., and Mullier, F. (2021). Pseudothrombocytopenia-A Review on Causes, Occurrence and Clinical Implications. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040594"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/08880010290097233","article-title":"Virus-Associated Immune Thrombocytopenic Purpura in Childhood","volume":"19","author":"Yenicesu","year":"2002","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management","volume":"156","author":"Mantadakis","year":"2010","journal-title":"J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 NCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e29326","DOI":"10.1002\/pbc.29326","article-title":"Immune Thrombocytopenia in a Child with COVID-19: Is It the Calm after the (Cytokine) Storm?","volume":"69","author":"Ceglie","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00277-020-04183-3","article-title":"Thrombocytopenia in COVID-19: Pathophysiology Matters","volume":"100","author":"Gavriilaki","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1111\/bjh.16783","article-title":"Severe COVID-19 Infection and Thrombotic Microangiopathy: Success Does Not Come Easily","volume":"189","author":"Gavriilaki","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.hoc.2013.02.004","article-title":"Congenital Thrombocytopenia: Clinical Manifestations, Laboratory Abnormalities, and Molecular Defects of a Heterogeneous Group of Conditions","volume":"27","author":"Kumar","year":"2013","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2003-05-1742","article-title":"Inherited Thrombocytopenia: When a Low Platelet Count Does Not Mean ITP","volume":"103","author":"Drachman","year":"2004","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kosmidou, A., Gavriilaki, E., and Tragiannidis, A. (2024). The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia?. Cancers, 16.","DOI":"10.3390\/cancers16081462"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102616","DOI":"10.1016\/j.autrev.2020.102616","article-title":"Pathogenesis of Immune Thrombocytopenia in Common Variable Immunodeficiency","volume":"19","author":"Tinazzi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/09612033221108853","article-title":"The Challenges in Diagnosing Pediatric Primary Antiphospholipid Syndrome","volume":"31","author":"Demir","year":"2022","journal-title":"Lupus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2023-186958","article-title":"High Titer ANA at Pediatric ITP Presentation Associated with Progression to Systemic Lupus Erythematosus","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2020.271106","article-title":"Long Term Follow-up of Pediatric-Onset Evans Syndrome: Broad Immunopathological Manifestations and High Treatment Burden","volume":"107","author":"Pincez","year":"2022","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1538-7836.2003.00091.x","article-title":"Prospective Evaluation of the Immunobead Assay for the Diagnosis of Adult Chronic Immune Thrombocytopenic Purpura (ITP)","volume":"1","author":"McMillan","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00043426-200411000-00007","article-title":"Long-Term Outcome of Chronic Idiopathic Thrombocytopenic Purpura in Children","volume":"26","author":"Jayabose","year":"2004","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous Immunoglobulin vs Observation in Childhood Immune Thrombocytopenia: A Randomized Controlled Trial","volume":"132","author":"Uiterwaal","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12185-020-02977-9","article-title":"High-Dose Dexamethasone as a Replacement for Traditional Prednisone as the First-Line Treatment in Children with Previously Untreated Primary Immune Thrombocytopenia: A Prospective, Randomized Single-Center Study","volume":"112","author":"Ma","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e29447","DOI":"10.1002\/pbc.29447","article-title":"Thrombopoietin Receptor Agonists and Rituximab for Treatment of Pediatric Immune Thrombocytopenia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials","volume":"69","author":"Ayad","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e30173","DOI":"10.1002\/pbc.30173","article-title":"Pediatric Refractory Immune Thrombocytopenia: A Systematic Review","volume":"70","author":"Ibrahim","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.19072","article-title":"A Proposal for New Definition (s) and Management Approach to Paediatric Refractory ITP: Reflections from the Intercontinental ITP Study Group","volume":"203","author":"Neunert","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune Thrombocytopenic Purpura (ITP) Plasma and Purified ITP Monoclonal Autoantibodies Inhibit Megakaryocytopoiesis in Vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.12832","article-title":"Impaired Proplatelet Formation in Immune Thrombocytopenia: A Novel Mechanism Contributing to Decreased Platelet Count","volume":"165","author":"Lev","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.2014.115634","article-title":"Immune Thrombocytopenia: Antiplatelet Autoantibodies Inhibit Proplatelet Formation by Megakaryocytes and Impair Platelet Production in Vitro","volume":"100","author":"Iraqi","year":"2015","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ejh.14262","article-title":"Cytokine Expression in Pediatric Patients with Immune Thrombocytopenia in Different Phases of Disease","volume":"113","author":"Luke","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A Review of Romiplostim Mechanism of Action and Clinical Applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V59.1.23.23","article-title":"Specificity of Autoantibodies in Autoimmune Thrombocytopenia","volume":"59","author":"Engelfriet","year":"1982","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kuwana, M., Okazaki, Y., and Ikeda, Y. (2014). Detection of Circulating B Cells Producing Anti-GPIb Autoantibodies in Patients with Immune Thrombocytopenia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086943"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","article-title":"Mechanisms of Response to Treatment in Autoimmune Thrombocytopenic Purpura","volume":"320","author":"Gernsheimer","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"Fc\u03b3RI and Fc\u03b3RIII on Splenic Macrophages Mediate Phagocytosis of Anti-Glycoprotein IIb\/IIIa Autoantibody-Opsonized Platelets in Immune Thrombocytopenia","volume":"106","author":"Norris","year":"2021","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-Mediated Complement Activation on Platelets Is a Common Finding in Patients with Immune Thrombocytopenic Purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2017-08-743229","article-title":"Mechanisms of Platelet Clearance and Translation to Improve Platelet Storage","volume":"131","author":"Quach","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell Receptor Regulates Hepatic Thrombopoietin Production via JAK2-STAT3 Signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 Stimulates Thrombopoiesis through Thrombopoietin: Role in Inflammatory Thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2015-01-569129","article-title":"Regulating Billions of Blood Platelets: Glycans and Beyond","volume":"126","author":"Grozovsky","year":"2015","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1056\/NEJM198505023121807","article-title":"An Antibody Cytotoxic to Megakaryocyte Progenitor Cells in a Patient with Immune Thrombocytopenic Purpura","volume":"312","author":"Hoffman","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V87.10.4245.bloodjournal87104245","article-title":"Differences in Serum Cytokine Levels in Acute and Chronic Autoimmune Thrombocytopenic Purpura: Relationship to Platelet Phenotype and Antiplatelet T-Cell Reactivity","volume":"87","author":"Semple","year":"1996","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of Regulatory T-Cell Changes in Patients with Idiopathic Thrombocytopenic Purpura Receiving B Cell-Depleting Therapy with Rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/bloodadvances.2017007021","article-title":"Mature Murine Megakaryocytes Present Antigen-MHC Class I Molecules to T Cells and Transfer Them to Platelets","volume":"1","author":"Zufferey","year":"2017","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/blood.2020009957","article-title":"Platelet EVs Contain an Active Proteasome Involved in Protein Processing for Antigen Presentation via MHC-I Molecules","volume":"138","author":"Marcoux","year":"2021","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed Anuclear Cell Death Delimits Platelet Life Span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12026-015-8760-z","article-title":"Imbalanced Expression of Bcl-XL and Bax in Platelets Treated with Plasma from Immune Thrombocytopenia","volume":"64","author":"Qiao","year":"2016","journal-title":"Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/jth.14419","article-title":"The Sensitivity and Specificity of Platelet Autoantibody Testing in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis of a Diagnostic Test","volume":"17","author":"Vrbensky","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.rpth.2023.100097","article-title":"Proceedings of the Immune Thrombocytopenia Summit: New Concepts in Mechanisms, Diagnosis, and Management","volume":"7","author":"Mahamad","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.2830370409","article-title":"Suppressed Natural Killer Cell Activity in Patients with Chronic Autoimmune Thrombocytopenic Purpura","volume":"37","author":"Semple","year":"1991","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.1200580","article-title":"Platelets Present Antigen in the Context of MHC Class I","volume":"189","author":"Chapman","year":"2012","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(72)90003-7","article-title":"Cellular Immunity to Autologous Platelets and Serum-Blocking Factors in Idiopathic Thrombocytopenic Purpura","volume":"1","author":"Clancy","year":"1972","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.hemonc.2017.01.001","article-title":"Study of CD4+, CD8+, and Natural Killer Cells (CD16+, CD56+) in Children with Immune Thrombocytopenic Purpura","volume":"10","author":"Helwa","year":"2017","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2015.11.005","article-title":"NK Cell Compartment in the Peripheral Blood and Spleen in Adult Patients with Primary Immune Thrombocytopenia","volume":"177","author":"Ebbo","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100822","DOI":"10.1016\/j.blre.2021.100822","article-title":"Immune Thrombocytopenia: A Review of Upfront Treatment Strategies","volume":"49","author":"Kochhar","year":"2021","journal-title":"Blood Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.1998.tb01239.x","article-title":"Short-course Oral Prednisone Therapy in Children Presenting with Acute Immune Thrombocytopenic Purpura (ITP)","volume":"87","author":"Carcao","year":"1998","journal-title":"Acta Paediatr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0039-1684031","article-title":"First-Line Therapy for Immune Thrombocytopenia","volume":"39","author":"Mithoowani","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00043426-200312001-00012","article-title":"Mechanisms of Action of Therapeutics in Idiopathic Thrombocytopenic Purpura","volume":"25","author":"Cines","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_73","first-page":"253","article-title":"Recommendations for the Management of Acute Immune Thrombocytopenia in Children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology","volume":"22","author":"Russo","year":"2024","journal-title":"Blood Transfus."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1423-0410.2002.tb05268.x","article-title":"Mechanism of Action of IVIG in ITP","volume":"83","author":"Lazarus","year":"2002","journal-title":"Vox Sang."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation Is a Mechanism of Fc-Independent Platelet Clearance and a Therapeutic Target in Immune Thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cao, Q., Zhu, H., Xu, W., Zhang, R., Wang, Y., Tian, Z., and Yuan, Y. (2023). Predicting the Efficacy of Glucocorticoids in Pediatric Primary Immune Thrombocytopenia Using Plasma Proteomics. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1301227"},{"key":"ref_77","first-page":"340","article-title":"Efficacy of Combined Intravenous Immunoglobulins and Steroids in Children with Primary Immune Thrombocytopenia and Persistent Bleeding Symptoms","volume":"12","author":"Parodi","year":"2014","journal-title":"Blood Transfus."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of Autoantibody Specificity and Response to Intravenous Immunoglobulin G Therapy in Immune Thrombocytopenia: A Multicenter Cohort Study","volume":"12","author":"Peng","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/jth.15232","article-title":"Biological Stratification of Clinical Disease Courses in Childhood Immune Thrombocytopenia","volume":"19","author":"Schmidt","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jth.15125","article-title":"A Clinical Prediction Score for Transient versus Persistent Childhood Immune Thrombocytopenia","volume":"19","author":"Schmidt","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.yapd.2024.02.007","article-title":"Pediatric Immune Thrombocytopenia","volume":"71","author":"Gotesman","year":"2024","journal-title":"Adv. Pediatr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 Years after Response to Rituximab Therapy in Children and Adults with Immune Thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in Immune Thrombocytopenia: Gender, Age, and Response as Predictors of Long-term Response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/pbc.23130","article-title":"Response to Steroids Predicts Response to Rituximab in Pediatric Chronic Immune Thrombocytopenia","volume":"58","author":"Grace","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pbc.21965","article-title":"Use of Rituximab for Refractory Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS)","volume":"52","author":"Rao","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e12587","DOI":"10.1002\/rth2.12587","article-title":"Response to Rituximab in Children and Adults with Immune Thrombocytopenia (ITP)","volume":"5","author":"Harris","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective Phase 1\/2 Study of Rituximab in Childhood and Adolescent Chronic Immune Thrombocytopenic Purpura","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2008.07487.x","article-title":"Long-term Follow-up Analysis after Rituximab Therapy in Children with Refractory Symptomatic ITP: Identification of Factors Predictive of a Sustained Response","volume":"144","author":"Parodi","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, Efficacy, and Immune Reconstitution after Rituximab Therapy in Pediatric Patients with Chronic or Refractory Hematologic Autoimmune Cytopenias","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Liang, Y., Zhang, L., Gao, J., Hu, D., and Ai, Y. (2012). Rituximab for Children with Immune Thrombocytopenia: A Systematic Review. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036698"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-014-1541-y","article-title":"Long-Term Follow-up of Children with Refractory Immune Thrombocytopenia Treated with Rituximab","volume":"99","author":"Matsubara","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I Treat Refractory Immune Thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_94","unstructured":"Atkinson, K. (2019). Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Clin. J. Oncol. Nurs., 23."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Garzon, A.M., and Mitchell, W.B. (2015). Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia. Front. Pediatr., 3.","DOI":"10.3389\/fped.2015.00070"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0b013e328356e909","article-title":"Thrombopoietin-Receptor Agonists","volume":"19","author":"Basciano","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"ref_97","first-page":"6162","article-title":"Efficacy of Romiplostim in the Treatment of ITP in Children: A Meta-Analysis","volume":"22","author":"Li","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1538-7836.2009.03440.x","article-title":"Development of Thrombopoietin Receptor Agonists for Clinical Use","volume":"7","author":"Ikeda","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e28840","DOI":"10.1002\/pbc.28840","article-title":"Fatigue Perception in a Cohort of Children with Chronic Immune Thrombocytopenia and Their Caregivers Using the PedsQL MFS: Real-life Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)","volume":"68","author":"Lassandro","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s12325-024-02951-5","article-title":"Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is It Time for Paediatric ITP?","volume":"41","author":"Provan","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/a-2247-4209","article-title":"Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics","volume":"44","author":"Gebetsberger","year":"2024","journal-title":"Hamostaseologie"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2040620720912992","DOI":"10.1177\/2040620720912992","article-title":"The Role of Romiplostim for Pediatric Patients with Immune Thrombocytopenia","volume":"11","author":"Grace","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in Children with Immune Thrombocytopenia: A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.htct.2022.09.1275","article-title":"Safety and Efficacy of Romiplostim in Children and Adolescents with Immune Thrombocytopenia: A Systematic Review","volume":"45","author":"Sequeira","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the Treatment of Children with Persistent and Chronic Immune Thrombocytopenia (PETIT): A Randomised, Multicentre, Placebo-Controlled Study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for Children with Chronic Immune Thrombocytopenia (PETIT2): A Randomised, Multicentre, Placebo-Controlled Trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A Randomized, Double-Blind Study of Romiplostim to Determine Its Safety and Efficacy in Children with Immune Thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ajh.27487","article-title":"Current State and Potential Applications of Neonatal Fc Receptor (FcRn) Inhibitors in Hematologic Conditions","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.19078","article-title":"Novel Therapeutics and Future Directions for Refractory Immune Thrombocytopenia","volume":"203","author":"Neufeld","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-Term Fostamatinib Treatment of Adults with Immune Thrombocytopenia during the Phase 3 Clinical Trial Program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2018-99-110482","article-title":"Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program","volume":"132","author":"Duliege","year":"2018","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"20406207231205430","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus Placebo in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia: LUNA 3 Phase III Study","volume":"14","author":"Kuter","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2024-199718","article-title":"Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)","volume":"144","author":"Kuter","year":"2024","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 Randomised Study of Avatrombopag, a Novel Thrombopoietin Receptor Agonist for the Treatment of Chronic Immune Thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e96683e8","DOI":"10.1097\/01.HS9.0000977180.96683.e8","article-title":"PB2623: Avatrombopag for the Treatment of Children with Persistent and Chronic Immune Thrombocytopenia","volume":"7","author":"An","year":"2023","journal-title":"Hemasphere"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/bjh.19342","article-title":"Efficacy and Safety of Avatrombopag in Chinese Children with Persistent and Chronic Primary Immune Thrombocytopenia: A Multicentre Observational Retrospective Study in China","volume":"204","author":"Wang","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.19553","article-title":"The Early and Rapid Response to Daratumumab in Children with Chronic Refractory Immune Thrombocytopenia from a Referral Single Centre of China","volume":"205","author":"Hu","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ejh.13925","article-title":"Herombopag Promotes Platelet Engraftment and Decreases Platelet Transfusion after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"110","author":"Zheng","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_120","unstructured":"(2024, December 12). Extension Study of Herombopag for Pediatric Patients with Chronic Immune Thrombocytopenia, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05685420?cond=NCT05685420&rank=1."},{"key":"ref_121","unstructured":"(2024, December 12). A Prospective, One-Arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06094881?cond=NCT06094881&rank=1."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.18864","article-title":"Outcomes of Switching to Avatrombopag Following Treatment Failure with Eltrombopag in Paediatric Immune Thrombocytopenia: A Real-World Study in China","volume":"202","author":"Cheng","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e31243","DOI":"10.1002\/pbc.31243","article-title":"Successful Avatrombopag Salvage Treatment in a Pediatric Patient with ANA-Positive Refractory Thrombocytopenia","volume":"71","author":"Turudic","year":"2024","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/1\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:31:27Z","timestamp":1759919487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/1\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cimb47010065"],"URL":"https:\/\/doi.org\/10.3390\/cimb47010065","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}